



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

DM4-SMCC

Cat. No.:	HY-126494		
CAS No.:	1228105-52-9		
Molecular Formula:	C ₅₄ H ₇₂ ClN ₅ O ₁₆ S		
Molecular Weight:	1114.69		
Target:	Drug-Linker Conjugates for ADC		
Pathway:	Antibody-drug Conjugate/ADC Related		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (112.14 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.8971 mL	4.4856 mL	8.9711 mL
	5 mM		0.1794 mL	0.8971 mL	1.7942 mL
	10 mM		0.0897 mL	0.4486 mL	0.8971 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	DM4-SMCC is a agent-linker conjugate for ADC with antitumor activity by using DM4 (an antitubulin agent), linked via the non-cleavable SMCC linker ^[1] .
IC ₅₀ & Target	Maytansinoids
In Vitro	Antibody-drug conjugates (ADCs) carry a highly potent small-molecule toxin covalently connected on the antibody via a proper linker. For therapeutic ADCs in cancer treatment, the antibody targets specific antigen of tumor cell surface with high binding affinity, thereafter the intact ADC was internalized into the tumor cells with the antigen and digested in the lysosome to release the antitumor toxin^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Singh R, et al. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. Mol Cancer Ther. 2016 Jun;15(6):1311-20.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA